THE SHARE: Change: +0.00 SEK (+0.83%) / Price: 0.12 SEK / Mar 16, 2026, 11:27 am (CET)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • Physiological Targeting
    • Functional Nanoparticles
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

MAR

  • 8 Mar, 2020
    Spago Nanomedical har slutfört rekryteringen till första dosgruppen i studie med SpagoPix
  • 9 Jan, 2020
    Lead compound appointed in the Tumorad® -project
  • 9 Jan, 2020
    Lead compound utsedd i Tumorad® -projektet
  • 28 Sep, 2019
    First patient dosed in the SPAGOPIX-01 study
  • 28 Sep, 2019
    Första patienten doserad i SPAGOPIX-01 studien
  • 5 Aug, 2019
    SpagoPix produktpatent i godkänns i Europa
  • 28 Mar, 2019
    Ytterligare 6,5 MSEK tillförs Spago Nanomedical
  • 27 Mar, 2019
    Spago Nanomedical AB tillförs 30,2 MSEK
  • 5 Mar, 2019
    Dr. Eugen Steiner föreslås till ny ordförande
  • 19 Feb, 2019
    Spago Nanomedical receives approval to initiate the clinical trial SPAGOPIX-01
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 9
  • Previous
  • Next
Back

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2026 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications